Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Ph+ Adult ALL (GIMEMA LAL 0201)
NCT00376467Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Dec 2001
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by GIMEMA. Primary endpoints: Overall Complete Molecular Remission Rate at 6 months and Overall Complete Hematological Remission Rate at 30 days. Started Dec 2001; status: completed.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00376467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376467.